| Project/Area Number |
26461503
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Infectious disease medicine
|
|---|
| Research Institution | Kobe University |
|---|
Principal Investigator |
SHIRAKAWA TOSHIRO 神戸大学, 科学技術イノベーション研究科, 教授 (70335446)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
堀田 博 神戸大学, 保健学研究科, 特命教授 (40116249)
片山 高嶺 京都大学, 生命科学研究科, 教授 (70346104)
|
|---|
| Co-Investigator(Renkei-kenkyūsha) |
KATAYAMA Takane 東京大学, 大学院生命科学研究科, 教授 (70346104)
|
|---|
| Project Period (FY) |
2014-04-01 – 2017-03-31
|
| Project Status |
Completed (Fiscal Year 2016)
|
| Budget Amount *help |
¥4,940,000 (Direct Cost: ¥3,800,000、Indirect Cost: ¥1,140,000)
Fiscal Year 2016: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2015: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
Fiscal Year 2014: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
|
|---|
| Keywords | 経口ワクチン / 慢性C型肝炎 / ビフィズス菌 / C型肝炎 |
|---|
| Outline of Final Research Achievements |
Currently, there are about 170 million HCV (hepatitis C virus) carriers worldwide. Although the treatment outcomes for chronic HCV infection have been improved with interferon and antiviral drugs, the curative rate is still not satisfactory. Recently, we have generated a novel oral HCV vaccine displaying HCV-NS3 protein on the cell surface of bifidobacteria and confirmed that it could induce the HCV-specific cellular immunity in a mouse experimental model. In this study, we have developed novel combinational oral vaccine therapy for HCV infection and confirmed its synergistic effect with interferon using a mouse syngeneic tumor model expressing NS3 protein.
|
